• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • Contact

News

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • Contact

News

News · February 4, 2020

La Presse: “Laurent Duvernay-Tardif’s knees at their best thanks to a “knee kinesiography with KneeKG” by EMOVI

emovi kneekg

"Unless he is injured during the game on Sunday, Laurent Duvernay-Tardif will be solid on both knees when he blocks to protect Patrick Mahomes, the Kansas City Chiefs quarterback, in order to allow …

News · November 15, 2019

CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.

centogene

Accelerating new rare disease therapies through collaboration agreement Cambridge, MA, USA & Rostock/Berlin, GERMANY,13 November 2019 – CENTOGENE (Nasdaq: CNTG),commercial-stage company …

News · November 8, 2019

Centogene AG Rings The Nasdaq Stock Market Closing Bell in Celebration of its IPO

…

News · October 29, 2019

CENTOGENE Announces Proposed Initial Public Offering of Common Shares

centogene

October 28, 2019 at 8:53 AM EDT CAMBRIDGE, Mass. and ROSTOCK, Germany, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare …

News · October 18, 2019

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS

Schlieren, Switzerland – October 16, 2019 – AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient …

News · October 14, 2019

Lilly’s REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval

antibiotics

The approval of REYVOW is significant because it represents the first new class of acute migraine treatment approved by the FDA in more than two decades INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- …

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 47
  • Go to Next Page »

Primary Sidebar

Secondary Sidebar

Additional News

TVM Life Science Innovation II SCSp Announces Investment in ImmunoRx Pharma, Inc.

January 19, 2021

Kent Imaging Inc. is accelerating its growth through a US$15M investment by TVM Life Science Innovation II SCSp

January 14, 2021

Emovi and SIAwards: 2nd interview on KneeKG and knee pain

January 7, 2021

Dentsply Sirona and Panthera Dental announce collaboration: fully digital workflow for custom-made sleep devices

November 13, 2020

TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm’s history

October 27, 2020

  • in

Copyright © 2021 · TVM Capital Life Science Venture Capital · Privacy Policy · Contact